多发性硬化症或视神经脊髓炎谱系障碍患者妊娠和哺乳期抗单克隆抗体治疗

Q4 Immunology and Microbiology
Chiyoko Nohara
{"title":"多发性硬化症或视神经脊髓炎谱系障碍患者妊娠和哺乳期抗单克隆抗体治疗","authors":"Chiyoko Nohara","doi":"10.1111/cen3.12724","DOIUrl":null,"url":null,"abstract":"<p>Multiple sclerosis (MS) and neuromyelitis optica (NMOSD) are more prevalent in women and mainly affecting young women, the majority of whom are of childbearing age. In addition, recent treatment algorithms suggest that patients who have poor prognostic factors are treated with highly effective disease-modifying drugs from the beginning. Monoclonal antibodies for MS or NMOSD are basically highly effective disease-modifying drugs. Therefore, young women with MS or NMOSD will have more opportunities to receive monoclonal antibody treatment than ever before. Currently, five monoclonal antibodies for MS or NMOSD are available in Japan: natalizumab and ofatumumab for MS, and eculizumab, satralizumab and inebilizumab for NMOSD. The pregnancy and breastfeeding of each monoclonal antibody drug is reviewed, and the evidence surrounding the safety of monoclonal antibody drugs during both pregnancy and breastfeeding in women with MS or NMOSD is discussed.</p>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Monoclonal antibody treatment during pregnancy and lactation in women with multiple sclerosis or neuromyelitis optica spectrum disorder\",\"authors\":\"Chiyoko Nohara\",\"doi\":\"10.1111/cen3.12724\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Multiple sclerosis (MS) and neuromyelitis optica (NMOSD) are more prevalent in women and mainly affecting young women, the majority of whom are of childbearing age. In addition, recent treatment algorithms suggest that patients who have poor prognostic factors are treated with highly effective disease-modifying drugs from the beginning. Monoclonal antibodies for MS or NMOSD are basically highly effective disease-modifying drugs. Therefore, young women with MS or NMOSD will have more opportunities to receive monoclonal antibody treatment than ever before. Currently, five monoclonal antibodies for MS or NMOSD are available in Japan: natalizumab and ofatumumab for MS, and eculizumab, satralizumab and inebilizumab for NMOSD. The pregnancy and breastfeeding of each monoclonal antibody drug is reviewed, and the evidence surrounding the safety of monoclonal antibody drugs during both pregnancy and breastfeeding in women with MS or NMOSD is discussed.</p>\",\"PeriodicalId\":10193,\"journal\":{\"name\":\"Clinical and Experimental Neuroimmunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Neuroimmunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12724\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12724","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 1

摘要

多发性硬化症(MS)和视神经脊髓炎(NMOSD)在女性中更为普遍,主要影响年轻女性,其中大多数是育龄女性。此外,最近的治疗算法表明,预后因素较差的患者从一开始就使用高效的疾病改良药物进行治疗。MS或NMOSD的单克隆抗体基本上是高效的疾病修饰药物。因此,患有多发性硬化症或NMOSD的年轻女性将比以往任何时候都有更多机会接受抗单克隆抗体治疗。目前,日本有五种针对MS或NMOSD的单克隆抗体:针对MS的那他珠单抗和ofatumumab,以及针对NMOSD的eculizumab、satralizumab和inebilizumab。综述了每种抗单克隆抗体药物的妊娠和母乳喂养情况,并讨论了抗单克隆抗体药在MS或NMOSD妇女妊娠和母乳期间的安全性证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Monoclonal antibody treatment during pregnancy and lactation in women with multiple sclerosis or neuromyelitis optica spectrum disorder

Multiple sclerosis (MS) and neuromyelitis optica (NMOSD) are more prevalent in women and mainly affecting young women, the majority of whom are of childbearing age. In addition, recent treatment algorithms suggest that patients who have poor prognostic factors are treated with highly effective disease-modifying drugs from the beginning. Monoclonal antibodies for MS or NMOSD are basically highly effective disease-modifying drugs. Therefore, young women with MS or NMOSD will have more opportunities to receive monoclonal antibody treatment than ever before. Currently, five monoclonal antibodies for MS or NMOSD are available in Japan: natalizumab and ofatumumab for MS, and eculizumab, satralizumab and inebilizumab for NMOSD. The pregnancy and breastfeeding of each monoclonal antibody drug is reviewed, and the evidence surrounding the safety of monoclonal antibody drugs during both pregnancy and breastfeeding in women with MS or NMOSD is discussed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical and Experimental Neuroimmunology
Clinical and Experimental Neuroimmunology Immunology and Microbiology-Immunology and Microbiology (miscellaneous)
CiteScore
1.60
自引率
0.00%
发文量
52
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信